Publications database

Deze pagina is gebaseerd op de meest recente beschikbare gegevens en biedt een overzicht van de huidige problematiek en opkomende drugsproblemen in Europa, met nadruk op de periode tot eind 2022. De...

Deze pagina is gebaseerd op de meest recente beschikbare gegevens en biedt een overzicht van de huidige problematiek en opkomende drugsproblemen in Europa, met nadruk op de periode tot eind 2022. De...

Patterns of drug use and developments in the drug market in Europe are becoming more complex and dynamic, with major implications for drug monitoring and research. This observation prompted the European Monitoring...

This is the final version of the questionnaire on drug use among prisoners at European level. The questionnaire is the results of several years of work in the field of drugs and...

On the basis of an external evaluation of the EU drugs strategy 2005-12, on 7 December 2012 the Justice and Home Affairs Council of the European Union endorsed a new EU drugs...

This regulation lays down the essential financial rules for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). It is based on and does not depart from the Commission Delegated Regulation...

Benzodiazepines are a widely prescribed group of medicines with a range of clinical uses, including the treatment of anxiety and insomnia and the management of alcohol withdrawal. For a number of reasons...

In this issue: Lisbon Addictions 2017 | New EMCDDA guide on responses | EMCDDA responds to increasing risks posed by new fentanils | IPA5 project draws to a close | Supporting global...

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the...

This report examines the triggers and dynamics of drug-related death in the seven EMCDDA Member States with the highest drug-related death (DRD) rates per population. The report explores whether between-country variations might...